#1 Clinical Trials Search in Europe

Levoleucovorin Disodium

Levoleucovorin Disodium, a crucial component in various cancer treatment regimens, is being studied in several clinical trials. These trials aim to evaluate its effectiveness when combined with other chemotherapy drugs for treating different types of cancer, including esophageal, pancreatic, and metastatic pancreatic ductal adenocarcinoma. The research focuses on improving patient outcomes, assessing safety profiles, and exploring new treatment strategies for these challenging cancers.

Table of Contents

What is Levoleucovorin Disodium?

Levoleucovorin disodium, also known as sodium levofolinate or disodium levofolinate, is a medication used in cancer treatment[1]. It belongs to a class of drugs called detoxifying agents for antineoplastic treatment, which means it helps to reduce the toxic effects of certain cancer medications[1].

What is Levoleucovorin Disodium Used For?

Levoleucovorin disodium is primarily used in combination with other chemotherapy drugs to treat various types of cancer, including:

  • Metastatic pancreatic ductal adenocarcinoma (PDAC): This is an advanced form of pancreatic cancer that has spread to other parts of the body[2].
  • Metastatic esophageal carcinoma: This refers to cancer of the esophagus that has spread beyond its original location[1].
  • Locally advanced pancreatic cancer: This is pancreatic cancer that has grown outside the pancreas but has not yet spread to distant parts of the body[3].

Levoleucovorin disodium is often used in combination with other chemotherapy drugs such as 5-fluorouracil (5-FU), irinotecan, and oxaliplatin. It helps to enhance the effectiveness of these drugs while reducing their toxic side effects[2].

How is Levoleucovorin Disodium Administered?

Levoleucovorin disodium is typically administered as an intravenous infusion, which means it is given directly into a vein[1]. The dosage and frequency of administration can vary depending on the specific treatment regimen and the patient’s individual needs. Some common dosing details include:

  • The medication is often given in doses measured in milligrams per square meter of body surface area (mg/m2).
  • A typical dose might be up to 200 mg/m2 per day[3].
  • Treatment cycles may last several months, with the total dose over the course of treatment potentially reaching up to 3600 mg/m2[2].

Current Clinical Trials

Levoleucovorin disodium is currently being studied in several clinical trials for various types of cancer:

  • A phase 3 study is evaluating its use in combination with pembrolizumab, lenvatinib, and chemotherapy for metastatic esophageal carcinoma[1].
  • Another study is investigating its use in a sequential treatment approach for locally advanced pancreatic cancer, combined with gemcitabine, paclitaxel, and FOLFIRINOX[3].
  • A phase 2 study is assessing its efficacy when combined with 5-FU and either NALIRI or NALIRINOX for metastatic pancreatic ductal adenocarcinoma that has progressed after initial treatment[2].

Potential Side Effects

As with any medication, levoleucovorin disodium can cause side effects. While not everyone experiences side effects, it’s important to be aware of potential issues. Common side effects may include:

  • Nausea and vomiting
  • Diarrhea
  • Fatigue
  • Decreased blood cell counts, which can increase the risk of infection or bleeding

It’s crucial to report any side effects to your healthcare provider, as they can often be managed effectively[1].

Precautions and Considerations

Before receiving levoleucovorin disodium, it’s important to inform your healthcare provider about:

  • Any allergies or hypersensitivities you may have
  • All medications you’re currently taking, including over-the-counter drugs and supplements
  • Any other medical conditions you have, especially kidney or liver problems
  • If you’re pregnant, planning to become pregnant, or breastfeeding

Your healthcare team will carefully consider these factors when determining if levoleucovorin disodium is appropriate for your treatment[2].

Aspect Details
Cancer Types Studied Esophageal cancer, Pancreatic cancer, Metastatic pancreatic ductal adenocarcinoma
Combination Therapies Used with various chemotherapy regimens (e.g., FOLFIRINOX, Gemcitabine, Nab-paclitaxel)
Administration Method Intravenous infusion
Dosage Range Typically 200 mg/m² per dose, with total amounts varying by study
Primary Objectives Assess efficacy, safety, and tolerability of combination treatments
Key Outcome Measures Progression-free survival, Overall survival, Objective response rate, Duration of response
Safety Monitoring Adverse events, laboratory assessments, physical examinations
Patient Selection Specific criteria for each study, including cancer type, stage, and previous treatments

FAQ

  • What is Levoleucovorin Disodium? Levoleucovorin Disodium is a medication used in cancer treatment. It helps enhance the effectiveness of certain chemotherapy drugs, particularly 5-fluorouracil (5-FU). It's often used to reduce the toxic effects of chemotherapy while maintaining its cancer-fighting properties.
  • In which types of cancer is Levoleucovorin Disodium being studied? Based on the clinical trials data provided, Levoleucovorin Disodium is being studied in esophageal cancer, pancreatic cancer, and metastatic pancreatic ductal adenocarcinoma.
  • How is Levoleucovorin Disodium administered? Levoleucovorin Disodium is typically administered through intravenous (IV) infusion. The exact dosage and frequency depend on the specific treatment regimen and the patient's condition.
  • What are the potential side effects of Levoleucovorin Disodium? While specific side effects aren't mentioned in the provided data, patients in these trials are monitored for adverse events. Common side effects of chemotherapy regimens may include nausea, fatigue, and changes in blood cell counts. Your healthcare team will discuss potential side effects based on your specific treatment plan.
  • How long do the clinical trials involving Levoleucovorin Disodium last? The duration of clinical trials can vary. In the provided data, treatment periods range from a few months to up to a year, depending on the specific trial and treatment regimen. Follow-up periods may extend beyond the treatment phase to monitor long-term outcomes.

Ongoing Clinical Trials on Levoleucovorin Disodium

  • Study of fluorouracil, irinotecan and oxaliplatin combination therapy for patients with metastatic pancreatic ductal adenocarcinoma who progressed after gemcitabine treatment

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Levoleucovorin Disodium: A medication used in cancer treatment to enhance the effectiveness of certain chemotherapy drugs, particularly 5-fluorouracil (5-FU). It helps reduce toxic effects while maintaining anti-cancer properties.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Pancreatic Ductal Adenocarcinoma (PDAC): A type of cancer that forms in the ducts of the pancreas, which is an organ located behind the stomach that helps in digestion and regulating blood sugar.
  • RECIST 1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a set of rules used to measure how well a cancer patient responds to treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • ECOG Performance Status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Duration of Response (DOR): The length of time that a tumor continues to respond to treatment without growing or spreading.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-pembrolizumab-lenvatinib-and-chemotherapy-for-patients-with-metastatic-esophageal-cancer/
  2. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-fluorouracil-irinotecan-and-oxaliplatin-combination-for-patients-with-metastatic-pancreatic-cancer-after-gemcitabine-treatment/
  3. http://clinicaltrials.eu/trial/study-on-sequential-treatment-with-gemcitabine-paclitaxel-and-folfirinox-for-patients-with-locally-advanced-pancreatic-cancer/